Emma Jonasson
Overview
Explore the profile of Emma Jonasson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ranji P, Jonasson E, Andersson L, Filges S, Santamaria M, Vannas C, et al.
J Transl Med
. 2024 Apr;
22(1):389.
PMID: 38671504
Background: Myxoid liposarcoma (MLS) displays a distinctive tumor microenvironment and is characterized by the FUS::DDIT3 fusion oncogene, however, the precise functional contributions of these two elements remain enigmatic in tumor...
2.
Gustafsson A, Jonasson E, Stahlberg A, Landberg G
Cancer Commun (Lond)
. 2024 Apr;
44(6):695-699.
PMID: 38576182
No abstract available.
3.
Berger K, Persson E, Gregersson P, Ruiz-Martinez S, Jonasson E, Stahlberg A, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136303
Unraveling the complex network between cancer cells and their tumor microenvironment is of clinical importance, as it might allow for the identification of new targets for cancer treatment. Cytokines and...
4.
Jonasson E, Matuschek E, Kahlmeter G
J Antimicrob Chemother
. 2023 Oct;
78(12):2926-2932.
PMID: 37864550
Objectives: Antimicrobial resistance rates are continuously increasing, driving the need for rapid antimicrobial susceptibility testing (RAST) results, especially in the treatment of bloodstream infections. The EUCAST RAST method performed directly...
5.
Vannas C, Andersson L, Dolatabadi S, Ranji P, Linden M, Jonasson E, et al.
Biomedicines
. 2022 Mar;
10(3).
PMID: 35327426
The therapeutic options for patients with relapsed or metastatic myxoid liposarcoma (MLS) remain scarce and there is currently no targeted therapy available. Inhibition of the HSP90 family of chaperones has...
6.
Dolatabadi S, Jonasson E, Andersson L, Santamaria M, Linden M, Osterlund T, et al.
Front Oncol
. 2022 Feb;
12:816894.
PMID: 35186752
Myxoid liposarcoma is one of the most common sarcoma entities characterized by FET fusion oncogenes. Despite a generally favorable prognosis of myxoid liposarcoma, chemotherapy resistance remains a clinical problem. This...
7.
Svanstrom A, Rosendahl J, Salerno S, Jonasson E, Hakansson J, Stahlberg A, et al.
Front Bioeng Biotechnol
. 2021 Dec;
9:711977.
PMID: 34869246
The field of 3D cell cultures is currently emerging, and material development is essential in striving toward mimicking the microenvironment of a native tissue. By using the response of reporter...
8.
Ghannoum S, Leoncio Netto W, Fantini D, Ragan-Kelley B, Parizadeh A, Jonasson E, et al.
Int J Mol Sci
. 2021 Feb;
22(3).
PMID: 33573289
The growing attention toward the benefits of single-cell RNA sequencing (scRNA-seq) is leading to a myriad of computational packages for the analysis of different aspects of scRNA-seq data. For researchers...
9.
Akerlund A, Jonasson E, Matuschek E, Serrander L, Sundqvist M, Kahlmeter G
J Antimicrob Chemother
. 2020 Aug;
75(11):3230-3238.
PMID: 32789506
Objectives: When bloodstream infections are caused by resistant bacteria, rapid antimicrobial susceptibility testing (RAST) is important for adjustment of therapy. The EUCAST RAST method, directly from positive blood cultures, was...
10.
Walsh C, Akrap N, Garre E, Magnusson Y, Harrison H, Andersson D, et al.
PLoS One
. 2020 Jul;
15(7):e0236187.
PMID: 32692762
The definitive characterization of common cancer stem cell (CSCs) subpopulations in breast cancer subtypes with distinct genotypic and phenotypic features remains an ongoing challenge. In this study, we have used...